|
|
|
|
||
Prothena's (PRTA) Overweight Rating Reaffirmed at Cantor Fitzgerald11-28-2018 Prothena (NASDAQ:PRTA)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research note issued on Friday. Other analysts have also issued reports about the company. BidaskClub upgraded Prothena from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research upgraded Prothena from a “sell” rating to a “hold” rating in a research note on Friday, August 10th. Oppenheimer reiterated a “hold” rating on shares of Prothena in a research note on Sunday, November 11th. Finally, ValuEngine upgraded Prothena from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $36.67. Shares of PRTA opened at $11.48 on Friday. The firm has a market capitalization of $477.97 million, a price-to-earnings ratio of -2.82 and a beta of 2.63. Prothena has a 1 year low of $10.43 and a 1 year high of $47.84. Prothena (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.43. Prothena had a negative return on equity of 43.17% and a negative net margin of 18,276.97%. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.26 million. On average, equities research analysts predict that Prothena will post -4.01 EPS for the current year. A number of institutional investors have recently bought and sold shares of PRTA. Bank of Montreal Can grew its position in Prothena by 6.7% during the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock worth $100,000 after buying an additional 117 shares in the last quarter. Quantbot Technologies LP grew its position in Prothena by 672.7% during the second quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock worth $101,000 after buying an additional 1,628 shares in the last quarter. BlackRock Inc. grew its position in Prothena by 197.8% during the first quarter. BlackRock Inc. now owns 2,656 shares of the biotechnology company’s stock worth $110,000 after buying an additional 1,764 shares in the last quarter. Societe Generale purchased a new position in Prothena during the second quarter worth about $111,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Prothena by 187.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock worth $129,000 after buying an additional 1,549 shares in the last quarter. Prothena Company Profile Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis. See Also: Relative Strength Index
|
return to message board, top of board |